I don’t think some folks understand what even one EUA or approval for Leronlimab would be worth. And that’s just one indication. Yeah, yeah, yeah, we gotta get there first. We all know.
But $2 per? The board would be too embarrassed to bring that to shareholders. That’s a bankruptcy yard sale price tag.